Pharma BD Deal Intelligence
Novartis paid ~$5.7B for Chiron in 2006; the vaccines business it was built around chronically lost money, took a $1.1B impairment in 2014, and was dismantled via three separate divestitures by 2015 — the biopharma piece (Proleukin, TOBI) was the only durable value.
Full analysis, sources & comparables →Analysts initially questioned whether Novartis' $40/share offer was sufficient; the raised $45 bid brought the deal in line with sector valuation comparables.
An analyst called the $45/share bid 'a relatively good deal' but noted Chiron faces 'a number of challenges which have to be addressed,' particularly…
Novartis closed the Chiron deal at $5.1 billion and immediately stood up a new Vaccines & Diagnostics division, targeting $200 million in annual cost synergies…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Novartis announces deal to acquire remaining ~58% stake in Chiron at $45/share cash for ~$5.1B; gains influenza/vaccine franchise. Closed April 2006.
Novartis paid ~$5.7B for Chiron in 2006; the vaccines business it was built around chronically lost money, took a $1.1B impairment in 2014, and was dismantled via three separate divestitures by 2015 — the biopharma piece (Proleukin, TOBI) was the only durable value.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Chiron Corporation (this deal) | 2005 | $5.1B | 36 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2005 deals · Novartis AG deals